{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:36:41Z","timestamp":1792201001090,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009797","name":"Barrow Neurological Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008222","name":"Ben and Catherine Ivy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008222","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jpba.2024.116150","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T03:04:27Z","timestamp":1713236667000},"page":"116150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A validated LC-MS\/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients"],"prefix":"10.1016","volume":"245","author":[{"given":"William","family":"Knight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tigran","family":"Margaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Sanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artak","family":"Tovmasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jpba.2024.116150_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme-literature review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"13","key":"10.1016\/j.jpba.2024.116150_bib2","doi-asserted-by":"crossref","first-page":"8596","DOI":"10.1021\/acs.jmedchem.1c01946","article-title":"Glioblastoma: current status, emerging targets, and recent advances","volume":"65","author":"Thakur","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2024.116150_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canlet.2021.12.008","article-title":"Unravelling glioblastoma heterogeneity by means of single-cell RNA sequencing","volume":"527","author":"Hernandez Martinez","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jpba.2024.116150_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jpba.2024.116150_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood-brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist. Updat."},{"issue":"4","key":"10.1016\/j.jpba.2024.116150_bib6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-009-1050-5","article-title":"Temozolomide in malignant gliomas: current use and future targets","volume":"64","author":"Villano","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jpba.2024.116150_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.jpba.2024.116150_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yexcr.2014.07.003","article-title":"Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3","volume":"329","author":"Beck","year":"2014","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.jpba.2024.116150_bib9","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1038\/s41598-018-22022-4","article-title":"Radiosensitization effect of talazoparib, a PARP inhibitor, on glioblastoma stem cells exposed to low and high linear energy transfer radiation","volume":"8","author":"Lesueur","year":"2018","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.jpba.2024.116150_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz3221","article-title":"Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.jpba.2024.116150_bib11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/neuonc\/noab003","article-title":"PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma","volume":"23","author":"Wu","year":"2021","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.jpba.2024.116150_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11523-021-00841-2","article-title":"Niraparib: a review in first-line maintenance therapy in advanced ovarian cancer","volume":"16","author":"Lee","year":"2021","journal-title":"Target Oncol."},{"issue":"2","key":"10.1016\/j.jpba.2024.116150_bib13","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e12","article-title":"A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)\/NIRVANA-R trial","volume":"33","author":"Park","year":"2022","journal-title":"J. Gynecol. Oncol."},{"issue":"98","key":"10.1016\/j.jpba.2024.116150_bib14","doi-asserted-by":"crossref","first-page":"37080","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"10.1016\/j.jpba.2024.116150_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e15066","article-title":"Tissue distribution and brain penetration of niraparib in tumor bearing mouse models and its clinical relevance","volume":"39","author":"Gada","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.jpba.2024.116150_bib16","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1200\/JCO.2023.41.16_suppl.2069","article-title":"A phase 0\/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma","volume":"41","author":"Mehta","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jpba.2024.116150_bib17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s11095-022-03246-6","article-title":"Unbound brain-to-plasma partition coefficient, K(p,uu,brain)-a game changing parameter for CNS drug discovery and development","volume":"39","author":"Loryan","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2024.116150_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121925","article-title":"Development and validation of an integrated LC-MS\/MS assay for therapeutic drug monitoring of five PARP-inhibitors","volume":"1138","author":"Bruin","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"3","key":"10.1016\/j.jpba.2024.116150_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4758","article-title":"Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS\/MS","volume":"34","author":"Krens","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2024.116150_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115758","article-title":"Development and validation of a sensitive LC-MS\/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients","volume":"237","author":"Wei","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116150_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jchromb.2016.11.020","article-title":"Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine","volume":"1040","author":"van Andel","year":"2017","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"12","key":"10.1016\/j.jpba.2024.116150_bib22","first-page":"1127","article-title":"Bioanalytical method development and validation of niraparib in plasma samples by LC-MS\/MS","volume":"7","author":"V.G. Gorijavolu","year":"2017","journal-title":"Indo Am. J. Pharm. Res."},{"issue":"5","key":"10.1016\/j.jpba.2024.116150_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3174\/ajnr.A6025","article-title":"Non-contrast-enhancing tumor: A new frontier in glioblastoma research","volume":"40","author":"Lasocki","year":"2019","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.jpba.2024.116150_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.jpba.2024.116150_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jpha.2022.05.003","article-title":"Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS\/MS","volume":"12","author":"Margaryan","year":"2022","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2024.116150_bib26","unstructured":"U.S. Food and Drug Administration, Bioanalytical method validation guidance for industry. \u3008https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf\u3009)."},{"key":"10.1016\/j.jpba.2024.116150_bib27","article-title":"Guideline M10 on bioanalytical method validation and study sample analysis","year":"2022"},{"issue":"19","key":"10.1016\/j.jpba.2024.116150_bib28","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","article-title":"A phase 0 trial of ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic- and pharmacokinetic-guided expansion cohort","volume":"25","author":"Tien","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.jpba.2024.116150_bib29","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1021\/jm901188v","article-title":"Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors","volume":"52","author":"Jones","year":"2009","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jpba.2024.116150_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/1078-0432.CCR-21-1096","article-title":"A phase 0 trial of ceritinib in patients with brain metastases and recurrent glioblastoma","volume":"28","author":"Mehta","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.jpba.2024.116150_bib31","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-17-3348","article-title":"Phase 0 trial of AZD1775 in first-recurrence glioblastoma patients","volume":"24","author":"Sanai","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.jpba.2024.116150_bib32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T23:46:26Z","timestamp":1720655186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":32,"alternative-id":["S0731708524001900"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116150","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A validated LC-MS\/MS method for determination of neuro-pharmacokinetic behavior of niraparib in brain tumor patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116150"}}